Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Taysha Gene Therapies Inc’s current trading price is -52.23% away from its 52-week high, while its distance from the 52-week low is 62.50%. The stock’s price range during this period has varied between $1.27 and $4.32. The company, active in the Healthcare sector, saw a trading volume of around 2.5 million for the day, considerably higher average daily volume of 2.06 million observed over the last three months.
Taysha Gene Therapies Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $4.32 on 06/13/24, with the lowest value being $1.27 on 11/14/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Taysha Gene Therapies Inc (TSHA) has experienced a quarterly decline of -4.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 422.93M and boasts a workforce of 52 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.54, with a change in price of -0.53. Similarly, Taysha Gene Therapies Inc recorded 2,208,404 in trading volume during the last 100 days, posting a change of -20.82%.
How TSHA’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for TSHA stands at 0.53. Similarly, the long-term debt-to-equity ratio is also 0.51.
TSHA Stock Stochastic Average
As of today, the raw stochastic average of Taysha Gene Therapies Inc over the past 50 days is 23.33%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 13.51%. Additionally, the Stochastic %K and %D values for the company were 13.51% and 17.07%, respectively, over the past 20 days.
TSHA Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 16.59% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -34.90%. Over the past 30 days, the price of TSHA has leaped by -3.57%. And in the last five days, it has fallen by -5.77%.
